The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
how are m8 making money - I know I've not had enough coffee yet, but doesn't say how m8 are getting paid - or am I missing something
Commercial Highlights:
-- Futura to receive payments on all sales of MED3000 from m8
-- Futura also eligible to receive up to $8.5 million in milestone payments based on deliverable sales volumes, including a small initial upfront payment
-- m8 is responsible for all local MED3000 development and regulatory costs in Brazil and Mexico as well as marketing expenses and ongoing pharmacovigilance and safety within the region
PaulFB - that is one of the best balanced posts Ive seen on here in a long time.
If the markets like ECR then the price wouldn't of dropped like it has. Hopefully the sell price of .014p is lowest and doesn't go any lower.
There are some extremely knowledgably people on this board and I bow down to that knowledge and expertise, but some times the enthusiasm gets a bit nauseating when the price keeps dropping.
Lets hope we get some decent news and gla
all very quiet from FUM.
I see that interim results are normally released in very late August or early Sept (well at least since 2016). So let hope we start hearing something in the next month or so...
oily - i'm the same.....have built a decent holding (well for me) so hoping now the BOD will start paying a decent divi. Let's hope we don't come across another big issue like ppi, covid, etc etc.
I wonder how much that cost and how much they have left in the bank.....guess we'll find out in the next set of results.
dgdg1, you are right - that will teach me not to be able read...damn it.....
I've also realised that the FDA trails have been pared back. Originally we were told that it's performance was to be judge against another product (calais) and it was to see if the gel worked after a period of time. According to this RNS it's just to see if people can follow basic instructions....which actually makes me laugh as I'm pretty sure most men know how to rub a gel on their "gland"....hahahaha.....
With this lower bench mark it should be cheaper (only needing 15 people) no mention of ethnicities (as previously mentioned and as DrNielsen says, we should be selling product in the EU and hopefully SE Asian before the trails in the US are completed
GCCRa, i disagree, the trial has been agreed and is very basic. They have about £10m in the bank which is, as they say, more than enough to see them through the FDA trial. Also they will start making some deals and will bring in, hopefully, more upfront payments.
but it is disappointing that we aren't having a launch in 2021.
the rns, imo, is fine as at least it gives us clarity of timelines, both on FDA trials and when they plan to launch (although I would have preferred it to be this year). Just means we have to wait a bit longer for the gravy train. But when they announce agreements it should help the shareprice.
Ukg - I was also hoping for a 2021 launch, but this is the first time they've actually told us when they plan to launch
Rereading this the RNS the amount of people that need testing is tiny and it's not even if it works. It all about what is written on the label and whether the user can actually use the gel without a quack being there.....so that shouldn't cost much.
"Manufacturing scale up and capacity to meet projected demand is progressing well in conjunction with commercial out-licensing agreements covering the remaining major regions and countries of the world with a number of interested parties." - Does this mean they have some agreements in place but haven't signed yet....as why else would they be increasing capacity in conjunction with agreements????
Notrac - they raised about £10m recently, so they've plenty of cash. - see this RNS
https://www.lse.co.uk/rns/FUM/result-of-placing-and-retail-offer-nth30lmud5zryx5.html
https://www.proactiveinvestors.co.uk/companies/news/954217/lloyds-banking-the--most-preferred--uk-bank-share-for-barclays-analysts-954217.html
Lloyds Banking Group PLC (LON:LLOY) is the most preferred bank share in the UK for analysts at Barclays, with “several reasons” why investors should stick with the sector despite its rally in recent months.
The banking sector has performed well since last autumn, helped by Britain’s vaccine roll-out and investors getting more comfortable about Brexit effects.
Investors who bought around last year’s lows and who are now thinking about moving on may miss out, Barclays said in a note to clients on Tuesday, as analysts think consensus earnings per share (EPS) expectations “could continue to improve and capital return could be sustainably better than anticipated”.
The Bank of England's Prudential Regulation Authority is soon due to give an update on whether banks can resume dividend payments.
The market is broadly expecting dividend restrictions to be eased but the Barclays analysts think investors “may be focusing too much on H2 2022 payouts. We think the sustainable yield is more relevant, which is a function of initial capital levels and organic capital generation.”
On this basis, NatWest Group PLC (LON:NWG) of the FTSE 100-listed lenders looks best.
Lloyds, however, is preferred overall as analysts see the strongest earnings outlook and see the biggest upside to consensus earnings, with Barclays current adjusted EPS estimates 20% and 15% ahead of consensus for 2022 and 2023.
“Most importantly we are positive on revenues, seeing a resilient NIM [net interest margin] outlook alongside stronger loan growth, given Lloyds’ faster growing consumer credit book,” analyst Aman Rakkar wrote.
“This may challenge Lloyds’ perception as ‘ex-growth’, although could also reignite the debate on its target CET1 ratio (rising to 14% from current 13.5%).”
Rakkar and his colleagues expect strong capital generation by Lloyds to translate into attractive capital return yields.
New chief executive Charline Nunn “raises strategic uncertainty but could also see action taken to drive non-interest income and costs” to lift the lender’s structural return on tangible equity.
Least preferred lenders are European names Commerzbank, UBS and ING.
cat 5 - I was thinking about the new deals they are planning on making. The SE Asian deal is already sorted.
But why sign the same kind of deal for the EU and UK when they've done all the work.
If FUM have managed to get the EU certificate, are in the process of increasing manufacturing of the product, why do they need to get some company involved.
They have got £10m in the bank, which is going to fund the US trial, which is leaving them a lot left over.
So, why get another company involved and lose 50%, based on the SE Asia deal (albeit that company is going to sort out the regulatory hurdles in SE Asia).
With all the hard work done, why don't they start marketing and selling the product themselves. I am aware that they've said they are a research and development company. But even so, to lose up to 50% for just marketing and selling seems a bit much.
This is a genuine question and wonder what other people think. I do hope that some deal is announced soon and it's not 50% they are giving away, as I said, they've done all the hard work.
Also would be nice to hear about TPR and CBD.
Oh and whilst I'm waiting to hear about the patent on all these products. I've been in the company over 18 months and thought that is roughly how long it takes to get sorted.
Why can't ECR release short and concise rns's like the one OMI just released.
If you look at ECR's announcement you have to dig really deep to find what we all want to know, which is how much gold in those hills :-).
OK, maybe I am being fussy, but when I read the OMI rns it tells me how much gold there is. Whereas with ECR I have to read a lot of scientific (boring) data before I see the grams per tonnage. ( i did say I was being fussy).
But let's hope we see some good results soon.
I'm very happy with the shareprice, my average is 27p (but like everyone else, would like it higher..lol).
I'm just disappointed with the RNS. This was a perfect time to give us an update on all their products. This morning RNS is all old news that's been in the public domain for a long time.
ECR (my other large holding) got slammed recently for not communicating more. Now they are providing a lot more detail and I think FUM could learn from them.
GLA lets hope for some decent news soon...
what a stupid RNS and what was the point.
What about TRP and CBD.....
let's hope more information is coming forthwith
imo they need to start communicating a lot better....
but still holding....
guess the market is upping the price in case of any information on Monday morning.....lets hope so....
although it's only a little lower than it was at the end of last week...
jtbear....I am pleasantly surprised i haven't been hammered....not like some other boards when I've been negative.
I like this board, as there are some very informative people who have taught me alot, not just on ECR, but on gold mining investing and what to look for.
My only issue is nearly everyone is extremely positive and I am not. Don't get me wrong, I hope this comes good. But I do tend to err on the side of caution and the share price is showing, I am right to be concerned.
But we do have a lot of news coming over the next few months. Lets hope we see some great results....
SnipVW - I am in agreement with you. In fact I almost took there smiles as if to say sucker.
I am very nervous of CB and would actually like him to be removed. He comes across as rather smug in my eyes. The capital raising was a disaster and god knows when we will get sentiment back. No amount of average RNS's are going to move the share price, as sentiment has been destroyed. We need to see some great results before we move forward. Let's hope the next few months we will see some good gold assays results
I'm in for £15k and currently I am 30% down, but that's not really much when it comes to penny stocks on AIM. I know this is a wild punt and definitely not for widow and orphans......
No doubt I will get hammered now for being negative.